SMTL ID : 8xb1.1

Crystal structure of FLT3 in complex with a Pyrazinamide Macrocycle derivative

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.85 Å

Oligo State

monomer

Ligands

1 x ZX3: 3^3-ethyl-5^4-morpholino-6,9-dioxa-2,4-diaza-3(2,6)-pyrazina-1(4,1)-piperidina-5(1,3)-benzenacycloundecaphane-3^5-carboxamide(Non-covalent)

ZX3.1: 13 residues within 4Å: Chain A: L.55, A.81, E.131, Y.132, C.133, C.134, Y.135, G.136, D.137, N.140, L.206, C.216, F.218 4 PLIP interactions: 4 interactions with chain A Hydrophobic interactions: A:L.55 Hydrogen bonds: A:E.131, A:C.133 Salt bridges: A:D.137

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Zheng, X. et al., Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations. Acs Pharmacol Transl Sci (2024)

Release Date

2024-12-11

Peptides

Receptor-type tyrosine-protein kinase FLT3: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Receptor-type tyrosine-protein kinase FLT3